Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer

European Urology

Volumn 71, Issue 3, 2017, Pages 462-475

  Alfred Witjes, J ^a   Lebret, Thierry ^b   Compérat, Eva M ^c   Cowan, Nigel C ^d   De Santis, Maria ^e   Bruins, Harman Maxim ^a   Hernández, Virginia ^f   Espinós, Estefania Linares ^g   Dunn, James ^h   Rouanne, Mathieu ^b   Neuzillet, Yann ^b   Veskimäe, Erik ⁱ   van der Heijden, Antoine G ^a   Gakis, Georgios ^j   Ribal, Maria J ^k  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^e UNIVERSITY OF WARWICK   (United Kingdom)

^f HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^g HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^h DERRIFORD HOSPITAL   (United Kingdom)

ⁱ TAMPERE UNIVERSITY HOSPITAL   (Finland)

^j UNIVERSITY OF TÜBINGEN   (Germany)

^k UNIVERSITY OF BARCELONA   (Spain)

more..

Author keywords

Bladder cancer; Cystectomy; Diagnosis; EAU; Follow up; Guidelines; Metastatic; Multimodality; Muscle invasive; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; IMMUNOLOGICAL ADJUVANT;

ARTICLE; BLADDER CANCER; BLADDER SURGERY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; COMORBIDITY; CONSERVATIVE TREATMENT; CYSTECTOMY; FOLLOW UP; HUMAN; METASTASIS; METASTATIC BLADDER CANCER; MINIMALLY INVASIVE SURGERY; MORBIDITY; MULTIMODALITY CANCER THERAPY; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; PRACTICE GUIDELINE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; URINARY DIVERSION; BLADDER; BLADDER TUMOR; CYSTOSCOPY; EUROPE; MEDICAL SOCIETY; PATHOLOGY; RADIOTHERAPY; SECONDARY; SMOOTH MUSCLE; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION; UROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; CYSTOSCOPY; EUROPE; HUMANS; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RADIOTHERAPY; SOCIETIES, MEDICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROLOGY;

EID: 84978435122     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.06.020     Document Type: Article

References (131)

1. [1] Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine - levels of evidence. Oxford Centre for Evidence-based Medicine Web site. http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/. Updated March 2009.
2. [2] Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49 (2013), 1374–1403.
3. [3] Burger, M., Catto, J.W., Dalbagni, G., et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63 (2013), 234–241.
4. [4] Chavan, S., Bray, F., Lortet-Tieulent, J., Goodman, M., Jemal, A., International variations in bladder cancer incidence and mortality. Eur Urol 66 (2014), 59–73.
5. [5] Freedman, N.D., Silverman, D.T., Hollenbeck, A.R., Schatzkin, A., Abnet, C.C., Association between smoking and risk of bladder cancer among men and women. JAMA 306 (2011), 737–745.
6. [6] Brennan, P., Bogillot, O., Cordier, S., et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 86 (2000), 289–294.
7. [7] Zelefsky, M.J., Housman, D.M., Pei, X., et al. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 83 (2012), 953–959.
8. [8] Liu, S., Yang, T., Na, R., et al. The impact of female gender on bladder cancer-specific death risk after radical cystectomy: a meta-analysis of 27,912 patients. Int Urol Nephrol 47 (2015), 951–958.
9. [9] Figueroa, J.D., Ye, Y., Siddiq, A., et al. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Human Mol Genet 23 (2014), 1387–1398.
10. [10] Hansel, D.E., Amin, M.B., Compérat, E., et al. A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur Urol 63 (2013), 321–332.
11. [11] Choi, W., Porten, S., Kim, S., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25 (2014), 152–165.
12. [12] Leissner, J., Koeppen, C., Wolf, H.K., Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. J Urol 169 (2003), 955–960.
13. [13] Burger, M., Grossman, H.B., Droller, M., et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 64 (2013), 846–854.
14. [14] Rajesh, A., Sokhi, H.K., Fung, R., Mulcahy, K.A., Bankart, M.J., Bladder cancer: evaluation of staging accuracy using dynamic MRI. Clin Radiol 66 (2011), 1140–1145.
15. [15] Lu, Y.Y., Chen, J.H., Liang, J.A., et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol 81 (2012), 2411–2416.
16. [16] Cowan, N.C., Turney, B.W., Taylor, N.J., McCarthy, C.L., Crew, J.P., Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour. BJU Int 99 (2007), 1363–1370.
17. [17] Yang, Z., Cheng, J., Pan, L., et al. Is whole-body fluorine-18 fluorodeoxyglucose PET/CT plus additional pelvic images (oral hydration-voiding-refilling) useful for detecting recurrent bladder cancer?. Ann Nucl Med 26 (2012), 571–577.
18. [18] Maurer, T., Souvatzoglou, M., Kubler, H., et al. Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol 61 (2012), 1031–1038.
19. [19] Lawrentschuk, N., Colombo, R., Hakenberg, O.W., et al. Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol 57 (2010), 983–1001.
20. [20] Rochon, P.A., Katz, J.N., Morrow, L.A., et al. Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. A prospective comparison of three comorbidity indices. Med Care 34 (1996), 1093–1101.
21. [21] Djaladat, H., Bruins, H.M., Miranda, G., Cai, J., Skinner, E.C., Daneshmand, S., The association of preoperative serum albumin level and American Society of Anesthesiologists (ASA) score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer. BJU Int 113 (2014), 887–893.
22. [22] Garg, T., Chen, L.Y., Kim, P.H., Zhao, P.T., Herr, H.W., Donat, S.M., Preoperative serum albumin is associated with mortality and complications after radical cystectomy. BJU Int 113 (2014), 918–923.
23. [23] Lughezzani, G., Sun, M., Shariat, S.F., et al. A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer. Cancer 117 (2011), 103–109.
24. [24] Mayr, R., May, M., Martini, T., et al. Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder. BJU Int 110 (2012), E222–E227.
25. [25] Morgan, T.M., Keegan, K.A., Barocas, D.A., et al. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. J Urol 186 (2011), 829–834.
26. [26] Abdollah, F., Sun, M., Schmitges, J., et al. Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study. Ann Surg Oncol 19 (2012), 309–317.
27. [27] Mayr, R., May, M., Martini, T., et al. Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder. Eur Urol 62 (2012), 662–670.
28. [28] Bolenz, C., Ho, R., Nuss, G.R., et al. Management of elderly patients with urothelial carcinoma of the bladder: guideline concordance and predictors of overall survival. BJU Int 106 (2010), 1324–1329.
29. [29] Cambier, S., Sylvester, R.J., Collette, L., et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus Calmette-Guérin. Eur Urol 69 (2016), 60–69.
30. [30] Sylvester, R.J., Brausi, M.A., Kirkels, W.J., et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57 (2010), 766–773.
31. [31] Malmstrom, P.U., Sylvester, R.J., Crawford, D.E., et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non–muscle-invasive bladder cancer. Eur Urol 56 (2009), 247–256.
32. [32] Dalbagni, G., Vora, K., Kaag, M., et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 56 (2009), 903–910.
33. [33] van den Bosch, S., Alfred Witjes, J., Long-term cancer-specific survival in patients with high-risk, non–muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 60 (2011), 493–500.
34. [34] Babjuk, M., Böhle, A., Burger, M., et al. Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1 and CIS). Edn. presented at: European Association of Urology annual meeting; March 12–14, Munich, Germany, 2016.
35. [35] Yates, D.R., Brausi, M.A., Catto, J.W., et al. Treatment options available for bacillus Calmette-Guérin failure in non–muscle-invasive bladder cancer. Eur Urol 62 (2012), 1088–1096.
36. [36] Sherif, A., Holmberg, L., Rintala, E., et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 45 (2004), 297–303.
37. [37] Krajewski, K.M., Fougeray, R., Bellmunt, J., et al. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Eur J Cancer 48 (2012), 1495–1502.
38. [38] Yoshida, S., Koga, F., Kobayashi, S., et al. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 83 (2012), e21–e27.
39. [39] Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005;48:202–5; discussion 205–6.
40. [40] Griffiths, G., Hall, R., Sylvester, R., Raghavan, D., Parmar, M.K., International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29 (2011), 2171–2177.
41. [41] Yuh, B.E., Ruel, N., Wilson, T.G., Vogelzang, N., Pal, S.K., Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. J Urol 189 (2013), 1682–1686.
42. [42] Lee, F.C., Harris, W., Cheng, H.H., et al. Pathologic response rates of gemcitabine/cisplatin versus methotrexate/vinblastine/Adriamycin/cisplatin neoadjuvant chemotherapy for muscle invasive urothelial bladder cancer. Adv Urol, 2013, 2013, 317190.
43. [43] Granfors, T., Tomic, R., Ljungberg, B., Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma. Scand J Urol Nephrol 43 (2009), 293–299.
44. [44] Huncharek, M., Muscat, J., Geschwind, J.F., Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis. Anticancer Res 18 (1998), 1931–1934.
45. [45] Nielsen, M.E., Palapattu, G.S., Karakiewicz, P.I., et al. A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. BJU Int 100 (2007), 1015–1020.
46. [46] Gore, J.L., Lai, J., Setodji, C.M., Litwin, M.S., Saigal, C.S., Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer 115 (2009), 988–996.
47. [47] Ayres, B.E., Gillatt, D., McPhail, S., et al. A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. BJU Int, 102, 2008, 1045.
48. [48] Davies, J.D., Simons, C.M., Ruhotina, N., Barocas, D.A., Clark, P.E., Morgan, T.M., Anatomic basis for lymph node counts as measure of lymph node dissection extent: a cadaveric study. Urology 81 (2013), 358–363.
49. [49] Dorin, R.P., Daneshmand, S., Eisenberg, M.S., et al. Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: a comparative mapping study. Eur Urol 60 (2011), 946–952.
50. [50] Wiesner, C., Salzer, A., Thomas, C., et al. Cancer-specific survival after radical cystectomy and standardized extended lymphadenectomy for node-positive bladder cancer: prediction by lymph node positivity and density. BJU Int 104 (2009), 331–335.
51. [51] Bruins, H.M., Veskimae, E., Hernandez, V., et al. The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. Eur Urol 66 (2014), 1065–1077.
52. [52] Mandel, P., Tilki, D., Eslick, G.D., Extent of lymph node dissection and recurrence-free survival after radical cystectomy: a meta-analysis. Urol Oncol 32 (2014), 1184–1190.
53. [53] Bi, L., Huang, H., Fan, X., et al. Extended vs non-extended pelvic lymph node dissection and their influence on recurrence-free survival in patients undergoing radical cystectomy for bladder cancer: a systematic review and meta-analysis of comparative studies. BJU Int 113 (2014), E39–E48.
54. [54] Bhatt, A., Nandipati, K., Dhar, N., et al. Neurovascular preservation in orthotopic cystectomy: impact on female sexual function. Urology 67 (2006), 742–745.
55. [55] Ali-El-Dein, B., Mosbah, A., Osman, Y., et al. Preservation of the internal genital organs during radical cystectomy in selected women with bladder cancer: a report on 15 cases with long term follow-up. Eur J Surg Oncol 39 (2013), 358–364.
56. [56] Novara, G., Catto, J.W., Wilson, T., et al. Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy. Eur Urol 67 (2015), 376–401.
57. [57] Bochner, B.H., Dalbagni, G., Sjoberg, D.D., et al. Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial. Eur Urol 67 (2015), 1042–1050.
58. [58] Stein, J.P., Lieskovsky, G., Cote, R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 (2001), 666–675.
59. [59] Wilson, T.G., Guru, K., Rosen, R.C., et al. Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel. Eur Urol 67 (2015), 363–375.
60. [60] Yuh, B., Wilson, T., Bochner, B., et al. Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy. Eur Urol 67 (2015), 402–422.
61. [61] Tang, K., Li, H., Xia, D., et al. Laparoscopic versus open radical cystectomy in bladder cancer: a systematic review and meta-analysis of comparative studies. PloS One, 9, 2014, e95667.
62. [62] Stein, J.P., Clark, P., Miranda, G., Cai, J., Groshen, S., Skinner, D.G., Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J Urol 173 (2005), 1163–1168.
63. [63] Hautmann, R.E., de Petriconi, R.C., Pfeiffer, C., Volkmer, B.G., Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 61 (2012), 1039–1047.
64. [64] Jentzmik, F., Schrader, A.J., de Petriconi, R., et al. The ileal neobladder in female patients with bladder cancer: long-term clinical, functional, and oncological outcome. World J Urol 30 (2012), 733–739.
65. [65] Ahmadi, H., Skinner, E.C., Simma-Chiang, V., et al. Urinary functional outcome following radical cystoprostatectomy and ileal neobladder reconstruction in male patients. J Urol 189 (2013), 1782–1788.
66. [66] Neuzillet, Y., Yonneau, L., Lebret, T., Herve, J.M., Butreau, M., Botto, H., The Z-shaped ileal neobladder after radical cystectomy: an 18 years experience with 329 patients. BJU Int 108 (2011), 596–602.
67. [67] Pruthi, R.S., Nielsen, M., Smith, A., Nix, J., Schultz, H., Wallen, E.M., Fast track program in patients undergoing radical cystectomy: results in 362 consecutive patients. J Am Coll Surg 210 (2010), 93–99.
68. [68] Karl, A., Buchner, A., Becker, A., et al. A new concept for early recovery after surgery for patients undergoing radical cystectomy for bladder cancer: results of a prospective randomized study. J Urol 191 (2014), 335–340.
69. [69] Lee, C.T., Chang, S.S., Kamat, A.M., et al. Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial. Eur Urol 66 (2014), 265–272.
70. [70] Nieuwenhuijzen, J.A., de Vries, R.R., Bex, A., et al. Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions. Eur Urol 53 (2008), 834–842 discussion 842–4.
71. [71] Madersbacher, S., Schmidt, J., Eberle, J.M., et al. Long-term outcome of ileal conduit diversion. J Urol 169 (2003), 985–990.
72. [72] Stein, J.P., Dunn, M.D., Quek, M.L., Miranda, G., Skinner, D.G., The orthotopic T pouch ileal neobladder: experience with 209 patients. J Urol 172 (2004), 584–587.
73. [73] Abol-Enein, H., Ghoneim, M.A., Functional results of orthotopic ileal neobladder with serous-lined extramural ureteral reimplantation: experience with 450 patients. J Urol 165 (2001), 1427–1432.
74. [74] Stein, J.P., Skinner, D.G., Results with radical cystectomy for treating bladder cancer: a ‘reference standard’ for high-grade, invasive bladder cancer. BJU Int 92 (2003), 12–17.
75. [75] Porter, M.P., Penson, D.F., Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol 173 (2005), 1318–1322.
76. [76] Large, M.C., Malik, R., Cohn, J.A., et al. Prospective health-related quality of life analysis for patients undergoing radical cystectomy and urinary diversion. Urology 84 (2014), 808–813.
77. [77] Singh, V., Yadav, R., Sinha, R.J., Gupta, D.K., Prospective comparison of quality-of-life outcomes between ileal conduit urinary diversion and orthotopic neobladder reconstruction after radical cystectomy: a statistical model. BJU Int 113 (2014), 726–732.
78. [78] Bartsch, G., Daneshmand, S., Skinner, E.C., Syan, S., Skinner, D.G., Penson, D.F., Urinary functional outcomes in female neobladder patients. World J Urol 32 (2014), 221–228.
79. [79] Deliveliotis, C., Papatsoris, A., Chrisofos, M., Dellis, A., Liakouras, C., Skolarikos, A., Urinary diversion in high-risk elderly patients: modified cutaneous ureterostomy or ileal conduit?. Urology 66 (2005), 299–304.
80. [80] Kilciler, M., Bedir, S., Erdemir, F., Zeybek, N., Erten, K., Ozgok, Y., Comparison of ileal conduit and transureteroureterostomy with ureterocutaneostomy urinary diversion. Urol Int 77 (2006), 245–250.
81. [81] Pycha, A., Comploj, E., Martini, T., et al. Comparison of complications in three incontinent urinary diversions. Eur Urol 54 (2008), 825–832.
82. [82] Stenzl, A., Sherif, H., Kuczyk, M., Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long term oncological, functional and quality of life results. Int Braz J Urol 36 (2010), 537–547.
83. [83] Stein, J.P., Skinner, D.G., Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 24 (2006), 296–304.
84. [84] Hautmann, R.E., de Petriconi, R.C., Volkmer, B.G., Lessons learned from 1,000 neobladders: the 90-day complication rate. J Urol 184 (2010), 990–994 quiz 1235.
85. [85] Nielsen, M.E., Mallin, K., Weaver, M.A., et al. Association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the National Cancer Data Base. BJU Int 114 (2014), 46–55.
86. [86] Porter, M.P., Gore, J.L., Wright, J.L., Hospital volume and 90-day mortality risk after radical cystectomy: a population-based cohort study. World J Urol 29 (2011), 73–77.
87. [87] Hautmann, R.E., Abol-Enein, H., Davidsson, T., et al. ICUD-EAU International Consultation on Bladder Cancer 2012: urinary diversion. Eur Urol 63 (2013), 67–80.
88. [88] Morgan, T.M., Barocas, D.A., Keegan, K.A., et al. Volume outcomes of cystectomy–is it the surgeon or the setting?. J Urol 188 (2012), 2139–2144.
89. [89] Finks, J.F., Osborne, N.H., Birkmeyer, J.D., Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 364 (2011), 2128–2137.
90. [90] Corcoran, A.T., Handorf, E., Canter, D., et al. Variation in performance of candidate surgical quality measures for muscle-invasive bladder cancer by hospital type. BJU Int 115 (2015), 230–237.
91. [91] Ravi, P., Bianchi, M., Hansen, J., et al. Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis. BJU Int 113 (2014), 733–740.
92. [92] Nuhn, P., May, M., Sun, M., et al. External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder. Eur Urol 61 (2012), 58–64.
93. [93] Abdollah, F., Gandaglia, G., Thuret, R., et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol 37 (2013), 219–225.
94. [94] Ghahestani, S.M., Shakhssalim, N., Palliative treatment of intractable hematuria in context of advanced bladder cancer: a systematic review. Urol J 6 (2009), 149–156.
95. [95] Solsona, E., Iborra, I., Collado, A., Rubio-Briones, J., Casanova, J., Calatrava, A., Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol 184 (2010), 475–480.
96. [96] Sondergaard, J., Holmberg, M., Jakobsen, A.R., Agerbaek, M., Muren, L.P., Hoyer, M., A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer. Acta Oncol 53 (2014), 1321–1328.
97. [97] Chung, P.W., Bristow, R.G., Milosevic, M.F., et al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol 25 (2007), 303–309.
98. [98] Shelley, M.D., Barber, J., Wilt, T., Mason, M.D., Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev, 2002, CD002079.
99. [99] Booth, C.M., Siemens, D.R., Li, G., et al. Curative therapy for bladder cancer in routine clinical practice: a population-based outcomes study. Clin Oncol (R Coll Radiol) 26 (2014), 506–514.
100. [100] Sternberg, C.N., Pansadoro, V., Calabro, F., et al. Can patient selection for bladder preservation be based on response to chemotherapy?. Cancer 97 (2003), 1644–1652.
101. [101] James, N.D., Hussain, S.A., Hall, E., et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366 (2012), 1477–1488.
102. [102] Krause, F.S., Walter, B., Ott, O.J., et al. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. Anticancer Res 31 (2011), 985–990.
103. [103] Ploussard, G., Daneshmand, S., Efstathiou, J.A., et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol 66 (2014), 120–137.
104. [104] Cohen, S.M., Goel, A., Phillips, J., Ennis, R.D., Grossbard, M.L., The role of perioperative chemotherapy in the treatment of urothelial cancer. Oncologist 11 (2006), 630–640.
105. [105] Leow, J.J., Martin-Doyle, W., Rajagopal, P.S., et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 66 (2014), 42–54.
106. [106] Svatek, R.S., Shariat, S.F., Lasky, R.E., et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 16 (2010), 4461–4467.
107. [107] Sternberg, C.N., Skoneczna, I., Kerst, J.M., et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16 (2015), 76–86.
108. [108] Galsky, M.D., Hahn, N.M., Rosenberg, J., et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 12 (2011), 211–214.
109. [109] Hussain, S.A., Palmer, D.H., Lloyd, B., et al. A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett 3 (2012), 855–859.
110. [110] Morales-Barrera, R., Bellmunt, J., Suarez, C., et al. Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur J Cancer 48 (2012), 1816–1821.
111. [111] Bamias, A., Dafni, U., Karadimou, A., et al. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Ann Oncol 24 (2013), 1011–1017.
112. [112] De Santis, M., Bellmunt, J., Mead, G., et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30 (2012), 191–199.
113. [113] De Santis, M., Bellmunt, J., Mead, G., et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II–results of EORTC study 30986. J Clin Oncol 27 (2009), 5634–5639.
114. [114] Galsky, M.D., Chen, G.J., Oh, W.K., et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 23 (2012), 406–410.
115. [115] von der Maase, H., Sengelov, L., Roberts, J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 (2005), 4602–4608.
116. [116] Sternberg, C.N., de Mulder, P., Schornagel, J.H., et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42 (2006), 50–54.
117. [117] Bellmunt, J., von der Maase, H., Mead, G.M., et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 30 (2012), 1107–1113.
118. [118] Henry, D.H., Costa, L., Goldwasser, F., et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29 (2011), 1125–1132.
119. [119] Yafi, F.A., North, S., Kassouf, W., First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol 18 (2011), e25–e34.
120. [120] Albers, P., Park, S.I., Niegisch, G., et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol 22 (2011), 288–294.
121. [121] Bellmunt, J., Theodore, C., Demkov, T., et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27 (2009), 4454–4461.
122. [122] Sweeney, P., Millikan, R., Donat, M., et al. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?. J Urol 169 (2003), 2113–2117.
123. [123] Siefker-Radtke, A.O., Walsh, G.L., Pisters, L.L., et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M.D. Anderson experience. J Urol 171 (2004), 145–148.
124. [124] Giannarini, G., Kessler, T.M., Thoeny, H.C., Nguyen, D.P., Meissner, C., Studer, U.E., Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution?. Eur Urol 58 (2010), 486–494.
125. [125] Huguet, J., Follow-up after radical cystectomy based on patterns of tumour recurrence and its risk factors. Actas Urol Esp 37 (2013), 376–382.
126. [126] Soukup, V., Babjuk, M., Bellmunt, J., et al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol 62 (2012), 290–302.
127. [127] Lehmann, J., Suttmann, H., Albers, P., et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol 55 (2009), 1293–1299.
128. [128] Picozzi, S., Ricci, C., Gaeta, M., et al. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. J Urol 188 (2012), 2046–2054.
129. [129] Sanderson, K.M., Cai, J., Miranda, G., Skinner, D.G., Stein, J.P., Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. J Urol 177 (2007), 2088–2094.
130. [130] Gupta, A., Atoria, C.L., Ehdaie, B., et al. Risk of fracture after radical cystectomy and urinary diversion for bladder cancer. J Clin Oncol 32 (2014), 3291–3298.
131. [131] Rouprêt, M., Babjuk, M., Böhle, A., et al. Guidelines on Urothelial Carcinomas of the Upper Urinary Tract. Edn. presented at: European Association of Urology annual meeting; March 12–14, Munich, Germany, 2016.